Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02339324 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
A Phase 1 study, sponsored by Yana Najjar.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02339324 is a Phase 1 study that has completed, run by Yana Najjar. The registered enrollment target is 31 participants.
The verdict
NCT02339324, a Phase 1 study, has completed, sponsored by Yana Najjar.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study plans to to estimate the safety profile of the combination biotherapy regimen consisting of standard-dose interferon alpha-2b (HDI) and anti-PD1 monoclonal antibody, Pembrolizumab, for the neoadjuvant therapy of locally/regionally advanced/recurrent melanoma. Also, the objectives of this trial include the evaluation of prognostic and predictive biomarkers, radiologic preoperative response rate, pathologic response rate, progression free survival and overall survival. Up to 30 evaluable patients will be accrued.
Interventions
- DRUG Pembrolizumab and high dose interferon alfa-2b (HDI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2015-03-06 |
| Est. Completion | 2019-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02339324
The ClinicalTrials.gov registry entry for NCT02339324 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yana Najjar, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab and high dose interferon alfa-2b (HDI) is the first listed.
NCT02339324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02339324 about?
NCT02339324 is a clinical study titled "Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b". This study plans to to estimate the safety profile of the combination biotherapy regimen consisting of standard-dose interferon alpha-2b (HDI) and anti-PD1 monoclonal antibody, Pembrolizumab, for the neoadjuvant therapy of locally/regionally advanced/recurrent melanoma. Also, the objectives of this ...
What is the current status of trial NCT02339324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2015-03-06. Estimated completion is 2019-11-02.
What interventions are being tested in trial NCT02339324?
The interventions under investigation include: Pembrolizumab and high dose interferon alfa-2b (HDI) (DRUG).
Who is sponsoring clinical trial NCT02339324?
This trial is sponsored by Yana Najjar, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.